Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction

American Journal of Cardiology

Volumn 81, Issue 10, 1998, Pages 1178-1181

  Oosterga, Margreeth ^a   Anthonio, Rutger L ^b   De Kam, Pieter Jan ^b   Kingma, J Herre ^b   Crijns, Harry J G M ^b   Van Gilst, Wiek H ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART DILATATION; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CAPTOPRIL; FEMALE; HUMANS; HYDROXYBUTYRATE DEHYDROGENASE; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; VENTRICULAR FUNCTION, LEFT;

EID: 0032525095     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00153-2     Document Type: Article

References (22)

1. 1. Kjekshus J, Swedberg K, Snapinn S, for the CONSENSUS Trial Group. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol 1992;69:103-107.
2. 2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325: 293-302.
3. 3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
4. 4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677
5. 5. Moore TJ, Crantz FR, Hollenberg NK, Koletsky RJ, Leboff MS, Swartz SL, Levine L, Podolsky S, Dluhy RG, Williams GH. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981;3:168-173.
6. 6. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in heart failure: relationship to renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-352.
7. 7. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-235.
8. 8. Nishimura H, Kubo S, Ueyama M, Kubota J, Kawamura K. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J 1989;117:100-105.
9. 9. Evans MA, Burnett JC, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol 1995;25:1445-1450.
10. 10. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-1555.
11. 11. Kingma JH, van Gilst WH, Peels CH, Dambrink J-HE, Verheugt FWA, Wielenga RP, for the CATS investigators. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Eur Heart J 1994;15:898-907.
12. 12. Laarse A van der, Kerkhof PLM, Vermeer F, Serruys PW, Hermens WT, Verheugt FWA, Bär FW, Krauss XH, van der Wal EE, Simoons ML. Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. Am J Cardiol 1988;61:1-7.
13. 13. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-585.
14. 14. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-331.
15. 15. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2: 349-360.
16. 16. Verheugt FWA, van der Laarse A, Funke-Küpper AJ, Sterkman LGW, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990;66:267-270.
17. 17. Alhaddad IA, Tkaczevski L, Siddiqui F, Mir R, Brown EJ. Aspirin enhances the benefits of late reperfusion on infarct size. Circulation 1995; 91:2819-2823.
18. 18. Hartman JC, Wall TM, Hulliger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
19. 19. Kalkman EAJ, van Suylen RJ, van Dijk JPM, Saxena PR, Schoemaker RG. Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. J Mol Cell Cardiol 1995;27:2483-2494.
20. 20. Van Gilst WH, Kingma JH, Peels CH, Dambrink J-HE, St John-Sutton M, on behalf of the CATS investigators. Which patient benefits from early angiotensin converting enzyme inhibition after myocardial infarction? J Am Coll Cardiol 1996;28:114-121.
21. 21. Dzau VJ, Swartz SL, Creager MA. The role of prostaglandins in the pathophysiology of and therapy for congestive heart failure. Heart Failure 1986;2:6-13.
22. 22. De Gaetano G, Cerletti C, Dejana E, Latini R. Pharmacology of platelet inhibition of humans: implications of the salicylate-aspirin interaction. Circulation 1985;72:1185-1193.